The Future of Breathing: Vivos Taps AI Tech to Redefine Sleep and Allergy Care

LITTLETON, Colo. – February 05, 2026 – In a move that signals a significant shift in the multi-billion-dollar sleep and wellness industry, Vivos Therapeutics (NASDAQ: VVOS) has announced a strategic collaboration with Silicon Valley's SoundHealth. The partnership will leverage Vivos' extensive network of over 2,000 healthcare providers to distribute SoundHealth’s groundbreaking, AI-driven technologies designed to actively treat nasal congestion and improve sleep quality, moving the market from passive monitoring to active, non-invasive intervention.

This collaboration brings together Vivos, a company known for its non-surgical Vivos Method for treating sleep-disordered breathing, and SoundHealth, a tech firm armed with the world's largest craniofacial dataset and a suite of FDA-cleared consumer health devices. Vivos will act as a reseller for SoundHealth's flagship products—the Sonu® Band for allergy relief and the Spatial Sleep™ band for sleep enhancement—equipping its network of trained dentists and medical professionals with a new suite of tools to address the foundational aspects of airway health.

A New Wave of AI-Powered Therapeutics

At the heart of the collaboration are SoundHealth's innovative wearables, which represent a new frontier in personalized, drug-free treatment. The Sonu® Band, celebrated as one of TIME Magazine's Best Inventions of 2025, is the world's first and only FDA-cleared, AI-enabled wearable designed to treat nasal congestion from both allergic and non-allergic rhinitis. Its mechanism is a departure from the pharmaceutical-heavy allergy market. Instead of drugs, it uses personalized vibro-acoustic neuromodulation—gentle sound waves tailored to the user's unique anatomy.

The process begins with a simple smartphone selfie. The app's AI constructs a CT-quality 3D model of the user’s craniofacial structure to generate a customized vibratory stimulus. This stimulus targets the nasal and sinus cavities, helping to reduce swelling and clear congestion. Clinical trials, including a multi-center, double-blinded study, have shown that the Sonu® Band provides relief comparable to leading intranasal steroids, but with zero reported side effects. For the millions who suffer from chronic congestion, it offers a non-pharmacological alternative that has been shown to provide relief in as little as 15 minutes.

Complementing the Sonu Band is the Spatial Sleep™ band, which targets sleep quality directly. Using a similar AI-driven personalization process, the device employs what SoundHealth calls Acoustic Sleep Harmonization™ technology. It delivers personalized low-frequency audio tones and vibrations through bone conduction transducers to guide the brain into deeper, more restorative sleep stages via a process known as neural entrainment. Clinical data indicates that 90% of users experienced a significant improvement in sleep quality, with an average 50% improvement in Insomnia Severity Index scores. Developed with input from experts at Stanford and Harvard, the device aims to promote rapid sleep onset and longer, deeper sleep without medication.

Expanding Access to Tackle a Silent Epidemic

The strategic power of this partnership lies in its potential for mass distribution. Vivos Therapeutics has spent years building a national network of dentists and healthcare providers trained in its Vivos Method, which focuses on addressing the root anatomical causes of obstructive sleep apnea (OSA). By integrating SoundHealth’s products, these providers can now offer a more comprehensive airway health solution.

“SoundHealth’s advanced technology across multiple product offerings is perfectly synergistic with Vivos treatment technology,” said Kirk Huntsman, CEO of Vivos Therapeutics, in the official announcement. He noted that the collaboration will add significant value to their existing offerings and reinforce Vivos' leadership in non-invasive treatments.

This expanded access is critical in addressing what health officials consider a silent epidemic. According to Vivos, over a billion people worldwide suffer from OSA, yet an estimated 80% of cases remain undiagnosed. This lack of diagnosis leaves millions vulnerable to associated chronic health conditions. The collaboration aims to change that by equipping frontline providers with accessible screening and treatment technologies. Vivos will gain access to SoundHealth’s smartphone-based facial scanning and voice biomarker technology, which can help clinicians screen, treat, and monitor patients' airway health in real time.

Paramesh Gopi, CEO of SoundHealth, echoed the sentiment of a shared mission. “Our Sonu platform was built to give people a practical, non-invasive way to help people breathe and sleep using FDA-cleared cutting edge drug free technology,” he stated. “This aligns perfectly with Vivos’ mission, and we are excited to collaborate with Vivos to bring our technology and data science to their providers and sleep and airway clinics.”

Connecting Airway Health to Overall Wellness

This partnership also underscores a growing understanding in the medical community: airway health is intrinsically linked to overall systemic health. Poor breathing, whether from allergies or structural issues, directly impacts sleep quality. In turn, sleep-disordered breathing is a major risk factor for severe chronic diseases. The American Heart Association has associated untreated sleep-disordered breathing with a 140% increased risk of heart failure and a 30% higher risk of coronary heart disease.

By offering solutions for both nasal congestion and sleep enhancement, the Vivos-SoundHealth collaboration provides a more holistic approach. A patient suffering from allergies that exacerbate their snoring or sleep apnea can now be treated with the Sonu® Band to open their nasal passages, potentially improving the efficacy of other sleep treatments or even their ability to comply with CPAP therapy. Airway-centric dentists have already noted that patients using the Sonu® Band report better breathing and reduced mouth breathing, a factor that can contribute to dental issues like dry mouth and tooth decay.

The technologies enable providers to move beyond treating symptoms to addressing foundational components of a patient’s well-being. By optimizing the airway, clinicians can help mitigate risks at a population scale, aligning with a broader shift toward preventative and integrative medicine.

Redefining the Sleep Technology Market

The collaboration is poised to make waves in the approximately $30 billion global sleep technology sector. For years, the consumer-facing market has been dominated by wearables that excel at passive tracking—monitoring sleep stages, heart rate, and respiratory rate. While valuable for data collection, these devices do not actively intervene to improve sleep or breathing.

The Vivos and SoundHealth partnership represents a definitive move toward active intervention. SoundHealth’s devices are designed not just to report on a problem but to physically resolve it through personalized, non-invasive therapy. This pivot is what Vivos CEO Kirk Huntsman calls “the next frontier of health technology.”

“We are witnessing a fundamental shift... moving from passive tracking to active airway interventions,” Huntsman concluded in his statement. “With nearly 80% of sleep-disordered breathing cases currently undiagnosed, the next frontier of health technology isn't just about monitoring; it is about physically optimizing the airway to treat critical health conditions and improve lives.”

By placing these advanced, clinically validated tools into the hands of a nationwide provider network, Vivos and SoundHealth are not just launching new products. They are building an ecosystem designed to make personalized, effective, and non-invasive airway care a new standard in the pursuit of better breathing, deeper sleep, and longer, healthier lives.